These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 2367793)

  • 1. [The treatment of Parkinson disease using the combination bromocriptine and levodopa].
    Dufresne JJ
    Rev Med Suisse Romande; 1990 Jun; 110(6):559-64. PubMed ID: 2367793
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 3. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
    Olsson JE
    Adv Neurol; 1990; 53():421-3. PubMed ID: 2239483
    [No Abstract]   [Full Text] [Related]  

  • 4. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 5. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa compared with bromocriptine in the treatment of Parkinson's disease.
    Godwin-Austen RB
    Adv Biochem Psychopharmacol; 1980; 23():261-5. PubMed ID: 7395616
    [No Abstract]   [Full Text] [Related]  

  • 7. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
    Olsson JE; Duchek M; Ekberg R; Fehling C; Johansson F; Johnels B; Lindvall B; Nordin G; Sidén A; Steg G
    Lakartidningen; 1993 Apr; 90(16):1545-8. PubMed ID: 8483351
    [No Abstract]   [Full Text] [Related]  

  • 9. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
    Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
    Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 11. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 13. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clozapine, a valuable contribution for the treatment of psychoses in Parkinson disease].
    Andersson U; Freccero-Rosman K; Aquilonius SM; Nylander B; Lindvall O; Odin P
    Lakartidningen; 1992 Dec; 89(49):4244-6. PubMed ID: 1461047
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bromocriptine versus levodopa in the early treatment of Parkinson's disease. 1st results after 2 years].
    Montastruc JL; Rascol O; Rascol A
    Therapie; 1988; 43(6):461-3. PubMed ID: 3227512
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experience with the use of parlodel in the treatment of Parkinson patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic agonists in Parkinsonism.
    Claveria LE; Teychenne PF; Calne DB; Petrie A; Bassendine MF
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096576
    [No Abstract]   [Full Text] [Related]  

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
    Todman DH; Oliver WA; Edwards RL
    Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.